Fuji Pharma Co., Ltd. (TYO:4554)
1,857.00
-21.00 (-1.12%)
Nov 13, 2026, 3:30 PM JST
Fuji Pharma Ratios and Metrics
Market cap in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
| 48,504 | 46,728 | 37,703 | 30,950 | 28,337 | 25,121 | |
Market Cap Growth | 20.06% | 23.94% | 21.82% | 9.22% | 12.80% | -11.60% |
Enterprise Value | 67,385 | 65,674 | 62,378 | 57,137 | 54,046 | 45,919 |
Last Close Price | 1857.00 | 1789.00 | 1507.21 | 1203.76 | 1070.44 | 919.38 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
PE Ratio | 16.70 | 16.51 | 12.57 | 5.04 | 8.25 | 9.32 |
Forward PE | 10.23 | 10.08 | 10.31 | 7.24 | 8.29 | 8.47 |
PS Ratio | 0.78 | 0.75 | 0.73 | 0.67 | 0.69 | 0.71 |
PB Ratio | 0.92 | 0.89 | 0.80 | 0.68 | 0.69 | 0.70 |
P/TBV Ratio | 1.25 | 1.21 | 1.14 | 0.94 | 0.92 | 0.99 |
P/FCF Ratio | 11.88 | 11.45 | 9.87 | 22.54 | - | - |
P/OCF Ratio | 7.86 | 7.57 | 6.50 | 7.46 | 14.78 | - |
PEG Ratio | - | 1.12 | 1.12 | 1.12 | 1.12 | 1.12 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
EV/Sales Ratio | 1.08 | 1.05 | 1.21 | 1.24 | 1.32 | 1.30 |
EV/EBITDA Ratio | 6.38 | 6.22 | 6.97 | 7.56 | 7.85 | 7.04 |
EV/EBIT Ratio | 10.60 | 10.33 | 12.50 | 14.72 | 14.01 | 12.15 |
EV/FCF Ratio | 16.51 | 16.09 | 16.33 | 41.61 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Debt / Equity Ratio | 0.54 | 0.54 | 0.66 | 0.64 | 0.70 | 0.69 |
Debt / EBITDA Ratio | 2.69 | 2.69 | 3.45 | 3.87 | 4.21 | 3.77 |
Debt / FCF Ratio | 6.95 | 6.95 | 8.10 | 21.31 | - | - |
Net Debt / Equity Ratio | 0.36 | 0.36 | 0.51 | 0.54 | 0.65 | 0.59 |
Net Debt / EBITDA Ratio | 1.79 | 1.79 | 2.65 | 3.26 | 3.87 | 3.22 |
Net Debt / FCF Ratio | 4.62 | 4.62 | 6.20 | 17.97 | -18.88 | -3.65 |
Asset Turnover | 0.65 | 0.65 | 0.56 | 0.53 | 0.51 | 0.51 |
Inventory Turnover | 1.74 | 1.74 | 1.58 | 1.51 | 1.39 | 1.50 |
Quick Ratio | 0.92 | 0.92 | 0.82 | 0.66 | 0.63 | 0.68 |
Current Ratio | 1.65 | 1.65 | 1.55 | 1.19 | 1.31 | 1.45 |
Return on Equity (ROE) | 5.70% | 5.70% | 6.49% | 14.17% | 8.92% | 7.87% |
Return on Assets (ROA) | 4.14% | 4.14% | 3.40% | 2.77% | 3.00% | 3.38% |
Return on Invested Capital (ROIC) | 8.02% | 8.04% | 5.32% | 4.18% | 4.84% | 5.59% |
Return on Capital Employed (ROCE) | 9.70% | 9.70% | 8.00% | 7.20% | 6.90% | 7.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Earnings Yield | 5.99% | 6.06% | 7.96% | 19.86% | 12.12% | 10.73% |
FCF Yield | 8.42% | 8.74% | 10.13% | 4.44% | -4.98% | -22.91% |
Dividend Yield | 2.64% | - | 2.95% | 3.34% | 3.17% | 3.38% |
Payout Ratio | 43.27% | 43.27% | 34.53% | 15.82% | 26.17% | 27.04% |
Buyback Yield / Dilution | -4.35% | -4.35% | -0.38% | -0.04% | -0.03% | 9.58% |
Total Shareholder Return | -1.71% | -4.35% | 2.57% | 3.30% | 3.14% | 12.96% |